Omega-3-Index Response to Eating Poultry Foods Naturally Enriched With Omega-3 Polyunsaturated Fatty Acids: A Randomized Controlled Trial in Healthy Saudi Adults

Diets low in seafood omega-3 polyunsaturated fatty acids (PUFAs) are very prevalent. Such diets have recently been ranked as the sixth most important dietary risk factor-1.5 million deaths and 33 million disability-adjusted life-years worldwide are attributable to this deficiency. Wild oily fish stocks are insufficient to feed the world's population, and levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in farmed fish have more than halved in the last 20 years.
The primary objective of this randomised, double-blinded, controlled nutritional trial will be to test if consumption of at least 4 servings of omega-3 PUFA-enriched chicken-meat and 4 enriched eggs per week, over a 4-month period, results in measurably higher blood levels of EPA and DHA in healthy Saudi adults.
This will be a randomised double-blind interventional study. Eighty adult male and female participants (age ≥ 18 years of age) will be asked to eat at least 4 portions of omega-3-PUFA enriched (or control) chicken-meat per week, and at least 4 omega-3-PUFA enriched (or control) eggs per week, for 4 months. Participants will be assessed at baseline and at monthly intervals for 4 months. Assessments at these visits will include; comprehensive lifestyle and medical history; food frequency questionnaire; 3 days food record; height, weight, waist and hip circumferences; blood sampling; participant well-being and adverse events. Measurement of plasma and red blood cell levels of EPA, DHA and Docosapentaenoic acid (DPA) will be performed at baseline and at study end using gas chromatography-mass spectroscopy.
The primary end point will be the change in red blood cell omega-3-index (sum of EPA and DHA expressed as percentage of total fatty acids in erythrocyte membranes) at 4 months. The nutritional trial will be analyzed on an intension to treat basis. Repeated measures ANOVA will be used to compare the two study groups. The study will be reported in accordance with the CONSORT (Consolidated Standards of Reporting Trials) 2010 statement.

开始日期2024-02-01

申办/合作机构

King Abdulaziz University

[+2]

NCT06151015 / Not yet recruitingN/AIIT

Testing the Combined Effect of Dietary Nitrate and Caloric Restriction on Cognitive and Vascular Function in Older Adults Living With Overweight or Obesity: A 28-Day Pilot Randomised Trial

This pilot study will compare the effect of combining dietary nitrate and caloric restriction versus dietary nitrate alone. The participant will be contacted, having responded to an advertisement on social media and posters, to attend the screening visit. They will be asked about their health status, suitability for MRI and availability. The investigators will use physical activity and eating attitude questionnaires. The investigators will also measure their height, weight, body mass index (BMI), and blood pressure (BP) and undertake blood tests. If they are eligible, they will be randomised to one of the two arms. The first group will consume nitrate-rich beetroot juice with a calorie-restricted diet for 28 days. The second group will drink the same juice with a weight-maintenance diet for the same period. The food and drinks will be provided. The outcome measures will be measured twice (at the baseline and end visits) to evaluate the change. The primary outcome is the cognitive function. The secondary outcomes are peripheral vascular health (BP and microvascular perfusion), cerebral vascular health (brain blood flow), anthropometry, body composition, and exhaled NO and nitrate concentrations. Also, the feasibility and accessibility of the study will be assessed.

开始日期2024-01-01

申办/合作机构

The University of Nottingham

[+1]

NCT06669039 / CompletedN/AIIT

Comparison of Computer Controlled Intra-ligamentary Local Anesthesia and Conventional Inferior Alveolar Nerve Block in Primary Molars Extractions - Randomized Clinical Trail

The goal of this clinical trial is to assess pain perception and compare the effectiveness between periodontal ligament anesthesia using Computer-controlled Local Anesthetic delivery system and the Conventional Inferior Alveolar Nerve Block during extraction of the primary molars.
The main questions it aims to answer are:
Is there a difference in pain perception and anesthesia effectiveness between the CC-ILA system and the traditional syringe when administering IANB in pediatric patients undergoing primary molar extractions.
Researchers will compare CC-ILA system to traditional syringe when administering IANB to see if there a difference in pain perception and anesthesia effectiveness.
Participants will:
Have their lower first primary molar extracted by receiving either periodontal ligament anesthesia using computer-controlled local anesthetic delivery system or the conventional inferior alveolar nerve bock.
Pain perception during the anesthesia process was measured using both objective criteria through the Sound-Eye-Motor scale and subjective assessment using Wong-Baker Faces Pain Rating Scale. The efficacy of anesthesia at various stages of the extraction procedure was evaluated using the Sound-Eye-Motor scale.

开始日期2023-11-17

申办/合作机构

King Abdulaziz University

100 项与 King Abdulaziz University 相关的临床结果

登录后查看更多信息

0 项与 King Abdulaziz University 相关的专利（医药）

登录后查看更多信息

33,710

项与 King Abdulaziz University 相关的文献（医药）

2025-02-01·PARASITOLOGY INTERNATIONAL

Chemical composition and bio-efficacy of agro-waste plant extracts and their potential as bioinsecticides against Culex pipiens mosquitoes

Article

作者: Baz, Mohamed M ; Alkhaibari, Abeer Mousa ; Alasmari, Saeed M ; Gattan, Hattan S ; Abdelkhalk, Heba F. ; Abdelkhalek, Heba F ; Alruhaili, Mohammed H ; El-Tabakh, Mohamed A M ; Alruhaili, Mohammed H. ; Baz, Mohamed M. ; Alasmari, Saeed M. ; El-Tabakh, Mohamed A.M. ; Gattan, Hattan S. ; Selim, Abdelfattah

Mosquitoes are considered one of the most lethal creatures on the planet and are responsible for millions of fatalities annually through the transmission of several diseases to humans. Green trash is commonly employed in agricultural fertilizer manufacturing and microbial bioprocesses for energy production. However, there is limited information available on the conversion of green waste into biocides. This study investigates the viability of utilizing green waste as a new biopesticide against Culex pipiens mosquito larvae. The current study found that plant extracts from Punica granatum (98.4 % mortality), Citrus sinensis (92 % mortality), Brassica oleracea (88 % mortality), Oryza sativa (81.6 % mortality), and Colocasia esculenta (53.6 % mortality) were very good at killing Cx. pipiens larvae 24 h post-treatment. The LC₅₀ values were 314.43, 370.72, 465.59, 666.67, and 1798.03 ppm for P. granatum, C. sinensis, B. oleracea, O. sativa, and C. esculenta, respectively. All plant extracts, particularly P. granatum extract (14.93 and 41.87 U/g), showed a significant reduction in acid and alkaline phosphate activity. Additionally, pomegranate extract showed a significant decrease (90 %) in field larval density, with a stability of up to five days post-treatment. GC-MS results showed more chemical classes, such as terpenes, esters, fatty acids, alkanes, and phenolic compounds. HPLC analysis revealed that the analyzed extracts had a high concentration of phenolic and flavonoid components. Moreover, there are many variations among these plants in the amount of each compound. The docking interaction showed a simulation of the atomic-level interaction between a protein and a small molecule through the binding site of target proteins, explaining the most critical elements influencing the enzyme's activity or inhibitions. The study's findings showed that the various phytochemicals found in agro-waste plants had high larvicidal activity and provide a safe and efficient substitute to conventional pesticides for pest management, as well as a potential future in biotechnology.

2025-01-01·FOOD CHEMISTRY

Developing natural microcapsules by encapsulating peptides for preserving Zanthoxylum Bungeanum

Article

作者: Batool, Zahra ; Sameen, Dur E ; Shen, Bairong ; Kamal, Mohammad Amjad

Natural edible microcapsules, were developed to improve the shelf life of Zanthoxylum bungeanum. Antimicrobial peptides, extracted from seeds of Sichuan pepper corn by ultrasound and microwave assisted extraction were encapsulated with nisin using water-in-oil-in-water (W/O/W) microencapsulation technique. Prepared microcapsules exhibited maximum encapsulation efficiency (ω %) of 30.20 at 3:1 ratio of extracted protein (EP) to gum Arabic (GA). After characterization, microcapsules were applied to Sichuan peppers by coating them during 10-days storage. Meanwhile, antimicrobial activity, total phenolic content (TPC), total flavonoid content (TFC) and radical scavenging activity (%) of treated pepper samples were evaluated; demonstrating that S3 and S4 microcapsules provided maximum antimicrobial activity (89.75 and 81.33 %), TPC (543.56 ± 3.87 and 481.40 ± 6.54 GAE/g), TFC (266.02 ± 2.64 QE/g and 306.96 ± 3.87 QE/g) and DPPH radical scavenging activity (78.06 ± 2.87 and 76.52 ± 1.67 %), respectively. Hence, S3 and S4 micro-capsules can be successfully employed as edible coating packaging to improve quality and shelf life of pepper.

2025-01-01·SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY

Design and synthesis of high quantum yield doped carbon nano probe derived from household sources for sensing of the anti-GERD drug pantoprazole

Article

作者: El-Maghrabey, Mahmoud ; El-Shaheny, Rania ; Magdy, Galal ; Al-Khateeb, Lateefa A ; Alshehri, Sultan ; Alsehli, Bandar R. ; Mahdi, Wael A. ; Alsehli, Bandar R ; El Hamd, Mohamed A. ; Al-Khateeb, Lateefa A. ; El Hamd, Mohamed A ; Mahdi, Wael A

This contribution aims to design and validate a new green, cheap, and fast approach for determining the anti-GERD drug pantoprazole in different matrices. New S and N-doped carbon nanomaterials (S,N-CNMs) have been prepared via microwave irradiation of a mixture of widely available household sources. Remarkably, the utilization of a blend of carbamide and thiocarbamide with table sugar yields S,N-CNMs exhibiting the utmost quantum yield (54 %), hydrophilicity, as well as stable, homogeneous, and diminutive particle size distribution. Fourier transform infrared spectroscopy, transmission electron microscopy, spectrophotometry, and fluorescence spectroscopy were applied to characterize the S,N-CNMs. The S,N-CNMs have been used as a turn-off fluorescence probe to determine pantoprazole via a synergism of the inner filter effect and static quenching mechanisms. The fluorescence quenching is linearly correlated to pantoprazole concentration over the range of 1.0-25.0 µg/mL with a detection limit of 0.16 µg/mL. The developed probe exhibited good selectivity for pantoprazole in the presence of variability of substances. Therefore, it was applied for quality control of pantoprazole in pharmaceutical tablets and vials with an average recovery % of 100.10 ± 0.77 % and 100.33 ± 0.92 %, respectively. Moreover, it was successfully implemented to examine the content uniformity of pantoprazole in tablets. Furthermore, the prepared S,N-CNMs have been successfully used for the analysis of pantoprazole in human plasma after a simple protein precipitation step with a recovery % of 97.88 ± 5.72 %. The greenness and blueness of the developed method have been positively assessed by recent tools showing the eco-friendliness and applicability of the developed method.

项与 King Abdulaziz University 相关的新闻（医药）

2024-06-11

·PRNewswire

Augnito Announces Strategic Investment to Accelerate Digital Health Innovation

DUBAI, UAE, June 11, 2024 /PRNewswire/ -- Augnito, a leading provider of Medical Voice AI solutions, has formed an alliance with Dharmendra Ghai, a prominent digital health evangelist based out of Qatar. Ghai's investment and expertise are set to accelerate the development and deployment of Augnito's cutting-edge healthcare technologies, enhancing patient experiences and operational efficiency across the global care continuum. With his keen eye and deep understanding of multiple markets, Ghai has established himself as an astute investor and trusted advisor to numerous companies. He currently serves on the board of VSee, a leading telehealth platform, and has made notable investments in various digital health companies — including Wellist, Meddy (now HeliumDoc), 4basecare, Mom's Belief, and NimbleHeart. Ghai is also a Digital Health Partner for the esteemed HIMSS (Healthcare Information and Management Systems Society), with an executive education from both MIT and Stanford, and an eHealth Consultant for the Health Ministry of Qatar. Augnito is at the forefront of SaaS innovation, providing state-of-the-art multi-lingual speech recognition, generative AI, and natural language processing technology to healthcare organizations worldwide. The company's suite of advanced voice-based solutions employs human-centric design principles to meet the evolving needs of both healthcare providers and patients. Augnito's recent partnerships with leading healthcare institutions in the Middle East, such as King's College Hospital London (Dubai), Cloud Solutions (HMG Group), Prime Healthcare, Dallah Hospitals, King Abdulaziz University Hospital, RAK Hospital, among several others, have showcased the company's commitment to driving innovation and creating significant impact for the region. Augnito's software is built-in compatible for native Arabic speakers (language and accents) and offers seamless enterprise IT solutions coupled with a differentiated approach to customer success. As an authority in healthcare informatics and innovation, Ghai's insights on regional business strategy, as well as patient security, medical imaging, and mHealth are expected to further accelerate Augnito's growth. The collaboration will facilitate a deeper understanding of the region's nuances and allow the Medical Voice AI innovator to tailor its products to better serve the Middle East. "We are thrilled to have Dharmendra Ghai as an investor," said Rustom Lawyer, Co-Founder and CEO of Augnito. "His expertise and vision are unparalleled, and we believe that he will be a catalyst in accelerating innovation — enabling us to bring even more refined and intuitive solutions to the market. We look forward to delivering enhanced healthcare experiences in the GCC, for patients and providers alike." Dharmendra Ghai expressed his enthusiasm, saying, "I am delighted to invest in Augnito, a company that has consistently demonstrated a commitment to innovation and excellence in healthcare technology. Their human-centric solutions and strong leadership team have positioned them at the forefront of the Medical Voice AI industry. I look forward to contributing to their growth and success in the global healthcare market." Both parties stated their unwavering commitment to ensuring that clinicians have access to the best tools and technologies to deliver superior patient care. About Augnito Augnito is an intuitive and advanced Voice-AI solution innovator, revolutionizing clinical documentation in the global healthcare market. Their proprietary AI-based clinical speech recognition, natural language understanding (NLU) C generative AI technologies enable ergonomic data entry with 99% accuracy, anywhere, from any device. Augnito helps streamline clinical workflows, makes healthcare intelligence securely accessible, and ensures that physicians have more time to concentrate on their primary concern: patient care. Their solutions are currently in use at more than 375 hospitals, across more than 25 countries. For more information or assistance, please visit augnito.ai or email [email protected] SOURCE Augnito

2024-05-20

·美通社

高中生科学家和工程师在 2024 年 Regeneron 国际科学与工程大奖赛中获得逾 900 万美元奖金

16 岁的 Grace Sun 在全球最大规模的大学前科学、技术、工程和数学 (STEM) 竞赛中展示了一款新型有机电化学晶体管，斩获 7.5 万美元的最高奖项。纽约州塔里敦和华盛顿 2024年5月20日 /美通社/ -- Regeneron Pharmaceuticals, Inc.（纳斯达克股票代码：REGN）和科学学会（以下简称 "学会"）宣布，在全球最大规模的大学前科学与工程竞赛 2024 年 Regeneron 国际科学与工程大奖赛 (Regeneron ISEF) 中，肯塔基州列克星敦 16 岁的 Grace Sun 荣膺 7.5 万美元的最高奖项，即 George D. Yancopoulos Innovator 奖，其命名用于纪念 Regeneron 联合创始人、董事会联席主席、总裁兼首席科学官 George D. Yancopoulos。其他顶级奖项颁发给了涉及二阶锥规划、微塑料过滤和多感官疗法治疗痴呆症的项目。恭喜 Krish Pai、Grace Sun 和 Michelle Wei，他们在加利福尼亚州洛杉矶举行的 2024 年 Regeneron 国际科学与工程博览会上名列前茅夺冠选手分别在两次颁奖典礼获得表彰：5 月 16 日的特别奖和 5 月 17 日上午的盛大颁奖典礼。根据入围项目的创造力、创新和科学探索的深度，本次竞赛向决赛入围者办法了逾 900 万美元的奖励。此次竞赛吸引了近 2000 名来自美国 49 个州以及全球近 70 个国家、地区和地域的年轻科学家。肯塔基州列克星敦 16 岁的 Grace Sun 拔得头筹，她在制造更先进有机电化学晶体管方面的研究，为她赢得 George D. Yancopoulos Innovator 奖和 7.5 万美元的奖金。她希望这种晶体管能够用于开发新的电子设备，帮助检测和治疗糖尿病、癫痫和器官衰竭等严重疾病。为了克服此前阻碍此类设备在体内有效运行的问题，Grace 开发了一种处理其有机成分的全新化学方法，大幅提高其实验室表现。加利福尼亚州圣何塞 17 岁的 Michelle Wei 开发出一种可以改善软件速度和效率的方法，应用领域广泛（如机器学习、交通和金融系统），成为两名青年科学家奖获奖者之一，奖金 5 万美元。Michelle 的新方法包括确定二阶锥编程问题的快速近似解，然后将初始锥体分成较小的锥体，这使其新算法能够大幅超过以前的方法。加利福尼亚州德尔玛 17 岁的 Krish Pai 在机器学习方面的研究，能找到可修改为生物降解塑料的微生物基因序列，夺得另外一项 Regeneron Young Scientist Award 奖。他研发的新软件 Microby 可对微生物数据库进行扫描，确定哪些微生物可通过基因改造转化为生物降解塑料。在测试中，他发现了两种可通过基因改造转化可降解塑料的微生物，预计成本比传统回收低十倍。科学学会主席兼首席执行官、《科学新闻》执行出版商 Maya Ajmera 表示："恭喜 2024 年 Regeneron 国际科学与工程大奖赛的获胜者。" "这些优秀学生表现出的聪明才智和决心，让我备受激励。这些学生虽然来自世界各地，背景和专业各不相同，但他们却证明了一点：通过团结一心，我们必将战胜当今世界面临的最艰巨挑战。对此我感到无比自豪。 Regeneron ISEF 为世界各地最优秀、最聪明的年轻科学家和工程师提供了一个全球舞台。Regeneron 和学会希望通过本次竞赛培养下一代 STEM 领导者，开发出更多可以打造更美好世界的解决方案。自 2020 年以来，Regeneron 已为约 240 万名学生提供了 STEM 体验，并且有望实现到 2025 年达到 250 万学生的目标。 Regeneron 联合创始人、董事会联席主席、总裁兼首席科学官、医学博士、博士 George D. Yancopoulos 表示："今年 Regeneron ISEF 决赛入围者的才华、才智和潜力令人备受鼓舞，恭喜他们取得如此非凡的成就。" "像 ISEF 这样的科学竞赛对我追求事业道路至关重要，它激发了我对抗疾病的热情。期待看到这些学生继续突破科学和技术的界限，为全人类创造积极且可持续的变革。" 本次竞赛的其他最高荣誉包括：德克萨斯州伍德兰兹 17 岁的 Justin Huang 和 Victoria Ou 以超声波去除水中塑料微粒的新原型过滤系统获得 Gordon E. Moore Award for Positive Outcomes for Future Generations 奖，奖金 5 万美元。在实验室测试中，高频声波产生的声力一次就能去除 84％至 94％的悬浮微塑料颗粒。目前，学生们正在努力扩大实验系统的规模，并对其进行微调。中国香港 17 岁的 Ingrid Wai Hin Chan 凭借使用多感官疗法治疗痴呆症患者的研究，斩获 Craig R. Barrett Award for Innovation 奖，奖金 10000 美元。她的综合疗法应用程序可以为患者提供个性化的沉浸式环境，借助虚拟现实头显训练身体和认知技能。Ingrid 对六名痴呆症患者进行了为期八周的研究，发现使用其原型的患者的认知功能在多个方面均有所改善。她认为，对于无法获得面对面的专业治疗的痴呆症患者，她的应用程序可以作为可行的选择。佛罗里达州瓦里科 15 岁的 Tanishka Balaji Aglave 对柑橘树黄龙病的天然替代疗法研究，斩获 H. Robert Horvitz Prize for Fundamental Research 奖，奖金 1 万美元。全球许多地区的柑橘种植业都受到这种疾病的影响，目前只能使用抗生素治疗。Tanishka 向受感染树木的树干注射了咖喱叶树提取物，并通过测试发现这种潜在的方法可有效且可持续地控制柑橘黄龙病。夏威夷檀香山 18 岁的 Maddux Alexander Springer 因研究纤维乳头瘤病 (FP) 而获得了 1 万美元的 Peggy Scripps Award for Science Communication 奖，纤维乳头瘤病是绿海龟的主要死亡原因。他在夏威夷卡内奥赫湾调查时发现有些海龟患有这种疾病，会导致罹患内外部肿瘤，妨碍日常生活。在分析了海龟的绿藻饮食后，Maddux 得出结论，这些濒临灭绝的海洋生物面临着多种生存威胁，除了 FP，还有废水、入侵性藻类和氨基酸精氨酸等因素。新泽西州哈肯萨克 17 岁的 Ria Kamat 、德克萨斯州休斯敦 17 岁的 Anna Oliva 和马萨诸塞州伍斯特 18 岁的 Shuhan Luo 获得了 Dudley R. Herschbach SIYSS 奖。该奖项以全包费用的形式，帮助获奖者在瑞典斯德哥尔摩诺贝尔周期间，参加斯德哥尔摩国际青年科学研讨会。爱尔兰基尔代尔省克莱恩 18 岁的 Jack Shannon 和北卡罗来纳州卡里 17 岁的 Nikhil Vemuri 获得了 EU Contest for Young Scientists 奖。其项目将代表 Regeneron ISEF 参加于今年 9 月在波兰卡托维兹举行的欧洲青年科学家大赛。欲了解有关最佳获胜者的更多信息以及获得视觉资产的权限，请访问： https://www.societyforscience.org/isef-2024-media-kit 。 Special Award ISEF 2024 决赛入围者的完整名单可在 https://www.societyforscience.org/press-release/regeneron-isef-2024-special-awards-winners 找到。除了最高奖获得者外，还有 450 多名决赛入围者因其创新研究获得了奖项和奖品，其中包括"一等奖" 得主，他们每人获得了 5000 美元的奖金。以下列出了 22 个类别中每个类别的一等奖获得者，最高奖项从中选出：动物科学，由科学学会赞助获奖者为夏威夷檀香山的 Maddux Alexander Springer 行为与社会科学，由科学协会赞助获奖者为加利福尼亚圣何塞的 Andrew Y. Liang 生物化学，由 Regeneron 赞助获奖者为纽约花园城的 Amy Hong Xiao 生物医学与健康科学，由的 Regeneron 赞助获奖者为新泽西州哈肯萨克的 Ria Kamat , Hackensack；中国上海的 Kevin Xuan Lei 生物医学工程，由 Alfred E. Mann Charities 赞助获奖者为加利福尼亚州都柏林的 Ayush Garg、帕洛阿尔托的 Divij Motwani、俄勒冈州波特兰的 Akash Ashish Pai 细胞和分子生物学，由 Regeneron 赞助获奖者为密歇根州比佛利山庄的Lara 和 Maya Sarah Hammoud 化学，由科学学会赞助获奖者为新墨西哥州阿尔伯克的 Akilan Sankaran；俄勒冈州波特兰的 Arjun Suresh Malpani 和 Siddharth Daniel d'Costa 计算生物学和生物信息学，由 Regeneron 赞助获奖者为纽约布朗克斯区的 Kun-Hyung Roh 地球与环境科学，由 Google.org 赞助获奖者为北卡罗来纳州达勒姆的 Nikhil Vemuri；德克萨斯州伍德兰兹的 Justin Yizhou Huang 和 Victoria Ou 嵌入式系统，由 HP 赞助获奖者为加拿大安大略省韦兰的 Chloe Rae 和 Sophie Rose Filion 能源：可持续材料和设计，由 Siemens Energy 赞助获奖者为拿大安大略省汉密尔顿市的 Alia Wahban 工程技术：静力学与动力学，由 Howmet Aerospace Foundation 赞助获奖者为日本东京的 Chiyo Nakatsuji、Bunkyoku；华盛顿州奥林匹亚的 Kevin Shen 环境工程，由 Jacobs 赞助获奖者为加利福尼亚州圣迭戈的Krish Pai；爱尔兰基尔代尔省克莱恩的 Jack Shannon 材料科学，由 Howmet Aerospace Foundation 赞助获奖者为肯塔基州列克星敦的 Grace Sun 数学，由 Akamai Foundation 赞助获奖者为德克萨斯州休斯敦的 Anna Oliva 微生物学，由 Schattner Foundation 赞助获奖者为加利福尼亚州尔湾的 Matthew Chang 物理与天文学，由 Richard F. Caris Charitable Trust II 赞助获奖者为华盛顿州博特尔市的 Harini Thiagarajan 和 Vishal Ranganath Yalla；马萨诸塞州伍斯特市的 Shuhan Luo 植物科学，由科学学会赞助获奖者为加利福尼亚州弗雷斯诺市的 Pauline Estrada；佛罗里达州多佛市的 Tanishka Balaji Aglave 机器人与智能机器，由 Regeneron 赞助获奖者为斯洛伐克特伦钦州的 Michal Lajciak；加拿大安大略省奥克维尔市的 Anthony Efthimiadis 系统软件，由 Microsoft 赞助获奖者为加利福尼亚州圣何塞的 Michelle Wei 科技增强艺术，由科学学会赞助获奖者为Anant Khandelwal、Sritan Motati 和 Siddhant Sood，弗吉尼亚州亚历山大市的 Siddhant Sood 转化医学，由 Regeneron 赞助获奖者为印第安纳州西拉斐特的 Zheng-Chi；中国香港的 Ingrid Wai Hin Chan 在这里查看 ISEF 2024 决赛入围者的完整名单： https://www.societyforscience.org/press-release/regeneron-isef-2024-full-awards . 点击此处查看所有决赛选手的研究项目： https://projectboard.world/isef 。关于 Regeneron 国际科学与工程大奖赛科学协会举办的 Regeneron 国际科学与工程大奖赛 (Regeneron ISEF) 竞赛已有 70 余年历史，是全球规模最大的面向高中生的科学竞赛。竞赛通过一个涵盖地方、区域和国家级别的全球科学博览会网络，鼓励数百万学生探索对科学研究的热情。每年春季会从这些学生中选择一批决赛入围者，角逐约 900 万美元的奖金和奖学金。 2019 年，Regeneron 成为 ISEF 的冠名赞助商，旨在帮助奖励和表彰全球最优秀、最聪明的年轻人，并鼓励其在 STEM 领域追求职业生涯，为世界带来积极影响。Regeneron ISEF 得到了其他赞助商社区的支持，包括 Akamai Foundation、Alfred E. Mann Charities、Aramco、加州理工学院、Google.org、Betty Moore Foundation、Howmet Aerospace Foundation、HP、Jacobs,、King Abdulaziz 及其 Companions Foundation for Giftedness and Creativity、Microsoft、国家地理学会、Richard F. Caris Charitable Trust II、Schmidt Futures 和 Rhodes Trust 共同发起的 Rise 倡议、Schattner Foundation、Siemens Energy、Annenburg Foundation、Ballmer Group、博通基金会、 Cesco Linguistic Services、Conrad N. Hilton Foundation、Edison International、Insaco、Oracle Academy、The Eli and Edythe Broad Foundation、The Ralph M. Parsons Foundation 及 US Army ROTC。其中很多都是来字各行各业的企业家。欲了解更多信息，请访问 https://www.societyforscience.org/isef/ 。关于科学学会作为科学的倡导者，科学学会致力于促进对科学的理解和欣赏，以及科学在人类进步中所扮演的重要角色。协会成立于 1921 年，拥有两份屡获殊荣的著名科学期刊《科学新闻》和《科学新闻探索》，为学生举办多项世界顶级科学研究竞赛，包括 Regeneron 科学奖、Regeneron 国际科学与工程大奖赛和 Thermo Fisher Scientific 青年创新者挑战赛，致力于推广和促进公平的外展计划，确保所有学生有机会追求 STEM 事业。作为一个 501(c)(3) 非营利会员组织，科学协会致力于为公众提供科学信息和教育，带来更多的激励与灵感。欲了解更多信息，请访问 www.societyforscience.org ，并在 Faceboo、Twitter、Instagram 和 Snapchat 上关注我们 (Society4Science)。关于 Regeneron 作为一家领先的生物技术公司，Regeneron（纳斯达克股票代码：REGN）致力于为严重疾病患者研发先进药物并进行商业化，帮助改变患者的生活。我们由医学科学家创办并领导，凭借独特的能力在科学-医学转化领域频繁斩获成功，目前已有多项治疗方法获得了批准，还有更多处于研发阶段的候选产品，其中大部分都是由内部实验室自主研发。我们的药物和研发项目旨在帮助罹患眼部疾病、过敏性和炎症性疾病、癌症、心血管和代谢性疾病、神经系统疾病、血液病症、传染病和罕见疾病的患者。 Regeneron 相信，我们作为企业公民的责任对实现企业使命至关重要。我们在履行企业责任时谨记三个目标：改善重病患者的生活，倡导诚信和卓越文化，打造可持续社区。Regeneron 荣幸地被列入道琼斯可持续发展世界指数（Dow Jones Sustainability World Index）和美国最具 "社区意识 "企业公民 50 强（Civic 50 list of the most "community-minded" companies in the U.S.）。全年中，Regeneron 通过志愿服务、公益和对等捐赠计划，实现员工赋权和回馈社会的目标。我们尤其注重在早期科学教育领域开展多项慈善行动，包括 Regeneron 科学奖和 Regeneron 国际科学与工程大奖赛 (ISEF) 。欲了解更多信息，请访问 www.regeneron.com 或在 LinkedIn 、 Instagram 、 Facebook 或 X 上关注 Regeneron。欲了解有关最佳获奖者和访问视觉资产的更多信息，请访问： https://www.societyforscience.org/isef-2024-media-kit 。媒体联系人 Joseph Brown，Regeneron joseph.brown2@regeneron.com Gayle Kansagor，科学学会 gkansagor@societyforscience.org

2023-10-20

·Healthcare IT News

Understanding NPHIES, KSA’s health information exchange

In the GCC, Saudi Arabia stands out as one of the leading territories spearheading the transformation of the healthcare landscape in the region. The country’s ambitious Vision 2030 goals encompass a range of objectives, which include enhancing healthcare services, digitising healthcare records, and elevating the overall efficiency of the nation’s healthcare system. Given the Kingdom’s resolute commitment to these healthcare advancements, it is unsurprising that Saudi Arabia is poised to introduce a comprehensive Health Information Exchange (HIE) system that has the potential to outshine its global counterparts. As the Medical Director of the Council of Health Insurance (CHI) in Saudi Arabia, Dr. Wail Yar is one of the key figures driving the programme. The CHI plays an integral role in the establishment of the country’s HIE known as NPHIES, which stands for the National Platform for Health and Insurance Exchange Services. “What makes NPHIES unique is that it has two parts: NPHIES Taameen [Insurance] and NPHIES Sehey [Health],” explains Dr. Yar. “This division is necessary due to how healthcare functions in Saudi Arabia, encompassing both public and private sectors.” The Kingdom’s public sector comprises four entities: the Ministry of Health (MoH), Saudi Arabian National Guard, Ministry of Interior, and Ministry of Education health offerings. “NPHIES Taameen serves as the infrastructure for the interaction between insurance companies and the private sector,” he states. Dr. Yar – who is also Assistant Professor of Preventive Medicine at King AbdulAziz University – is scheduled to appear at the 6th GCC eHealth Workforce Development Conference (eHWDC 2023) , taking place between 31 October and 2 November 2023 at Jumeirah Emirates Towers. The event will feature a dedicated panel where further details about NPHIES will be revealed. But just what do we know about it as of now? NPHIES TAAMEEN According to public records, the initial phase of NPHIES’ implementation commenced in 2020 and has steadily advanced since. The project comprises two parts: one for the insurance segment, known as Taameen, and is under the management of the CHI; and one for healthcare, referred to as Sehey, which is overseen by the Saudi MoH. As of now, NPHIES Taameen has achieved broader public accessibility, with approximately 75% of healthcare providers currently integrated into the system. “The CHI’s role, established two decades ago, was to mediate between insurance companies and healthcare providers. Before NPHIES Taameen was launched, hospitals sent requests directly to insurance companies, following the prior authorisation process,” says Dr. Yar. “Today, the NPHIES platform acts as the intermediary. Hospitals and insurance companies connect their systems to NPHIES. Hospital service requests now go through NPHIES, and insurance companies respond through the platform. The CHI can monitor and regulate these transactions, ensuring transparency and addressing any issues like fraud, misuse, or patient care delays.” He continues: “At present, 75% of private providers are already connected to NPHIES, and by the end of October 2023, we aim to achieve a 91% connection rate.” NPHIES SEHEY Similar to other HIEs, NPHIES Sehey will house comprehensive patient data, such as medication history, allergies, vaccination records, and outpatient visits. Currently, it is in the testing phase. It is anticipated that more will be revealed about NPHIES Sehey in the coming weeks. With NPHIES Taameen approaching 90% adoption by the end of October, the same percentage target is set for NPHIES Sehey but with a different timeframe. “Our goal is to reach 90% of the market,” reveals Dr. Yar. “From an insurance perspective, 90% of the market will already be linked to NPHIES Taameen by the end of October. “However, expanding to NPHIES Sehey will no doubt take more time; likely 3 to 5 years to achieve a similar level of integration. The process for hospitals is quite costly and complex; it’s not that easy to do. It requires a lot of manpower, equipment, education, technical implementation, and adoption. It's a significant undertaking.” Find out more about NPHIES during eHWDC 2023. Register to attend by visiting gccehealth.org .

100 项与 King Abdulaziz University 相关的药物交易

登录后查看更多信息

100 项与 King Abdulaziz University 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月22日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

早期临床1期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

百里香醌 ( E2F1 x MUC4 x PTEN )	牙龈炎更多	早期临床1期
Shikimic Acid	高血糖更多	临床前
Fused pyrazolopyridine 3FPP ( AHR )	乳腺癌更多	临床前
US11548919 ( env )专利挖掘	感染更多	药物发现
VIU-1005 ( SARS-CoV-2 S protein )	冠状病毒感染更多	无进展